AnaptysBio, Inc. Common Stock
ANAB
$56.80
-1.15%
AnaptysBio is a clinical-stage biotechnology company developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology, with a focus on immune cell modulating antibodies. The company is distinct for its wholly owned checkpoint agonists, including rosnilimab (PD-1 agonist) and ANB032 (BTLA agonist), targeting autoimmune and inflammatory diseases. The current investor narrative centers on the advancement of its lead pipeline candidates through Phase 2 trials, with recent positive clinical data and a strong cash position fueling optimism. The stock has seen significant attention due to its potential in treating rheumatoid arthritis, ulcerative colitis, and atopic dermatitis, with the market closely watching upcoming data readouts and regulatory milestones.…
ANAB
AnaptysBio, Inc. Common Stock
$56.80
Investment Opinion: Should I buy ANAB Today?
Rating: Buy. AnaptysBio offers a compelling risk/reward profile for investors with a high tolerance for volatility. The consensus Strong Buy rating and average target price of $89.63 imply +57.8% upside, while the low target of $70.00 still offers +23.2% upside. The thesis is driven by the potential of its checkpoint agonists in large autoimmune markets, supported by a strong cash position of $248.47M and a low debt-to-equity ratio of 0.38.
Sign up to view all
ANAB 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The strong analyst support, solid balance sheet, and promising pipeline provide a favorable backdrop. However, the binary nature of clinical trials and revenue volatility temper confidence. Key developments to watch include Phase 2 data readouts and any partnership announcements. If positive data emerges, the stance would be upgraded to high confidence; conversely, a trial failure would trigger a downgrade to bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AnaptysBio, Inc. Common Stock's 12-month outlook, with a consensus price target around $87.44 and implied upside of +54.0% versus the current price.
Average Target
$87.44
0 analysts
Implied Upside
+54.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $140
Analyst target range
AnaptysBio has coverage from 8 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.38). The average price target is $89.63, implying an upside of +57.8% from the current price of $56.80. The target range is $70.00 to $140.00, with the low target still representing a +23.2% upside, indicating that even the most bearish analyst sees value. The high target of $140.00 implies a +146.5% upside, suggesting significant potential if clinical trials succeed. Recent ratings have been consistently positive, with firms like Barclays, UBS, and Piper Sandler maintaining Overweight/Buy ratings, and no downgrades or negative actions in the past few months. The wide spread between low and high targets reflects the binary nature of clinical-stage biotech, where success can lead to massive upside but failure could result in significant downside.
Bulls vs Bears: ANAB Investment Factors
AnaptysBio presents a compelling bull case driven by strong analyst conviction, a robust cash position, and a promising pipeline targeting large autoimmune markets. The stock has already delivered +169% returns over the past year, and analysts see further upside. However, the bear case highlights the inherent risks of clinical-stage biotech: revenue is lumpy and dependent on one-time deals, operating losses are deep, and pipeline failure would be catastrophic. Currently, the bull case has stronger evidence given the consensus Strong Buy rating, the +58% average target upside, and the company's solid balance sheet. The most critical tension is the binary outcome of Phase 2 data readouts—success could propel the stock toward the $140 high target, while failure could send it back to single digits. Investors must weigh this binary risk against the substantial potential reward.
Bullish
- Strong Buy consensus with 58% upside: 8 analysts rate ANAB a Strong Buy (mean 1.38) with an average target of $89.63, implying +57.8% upside from $56.80. Even the lowest target of $70.00 offers +23.2% upside, indicating rare alignment among analysts.
- Massive 1-year outperformance: Stock surged +169.3% over the past year vs. S&P 500's +18.7%, reflecting a major re-rating on clinical progress. This momentum is supported by a 3-month gain of +12.8% and a 1-month gain of +3.3%.
- Strong cash position funds pipeline: With $248.47M in cash and a current ratio of 9.07, ANAB has ample runway to advance rosnilimab and ANB032 through Phase 2 trials without near-term dilution risk. Debt-to-equity is low at 0.38.
- High gross margin from collaboration revenue: Gross margin was 97.6% in Q1 2026, reflecting the lucrative nature of licensing deals. This demonstrates the potential for high profitability once revenue scales.
Bearish
- Revenue volatility from one-time deals: Q1 2026 revenue fell -8.0% YoY to $25.56M, while Q4 2025 spiked to $108.25M due to a licensing deal. Excluding such events, underlying revenue is inconsistent, making financial projections unreliable.
- Deep operating losses persist: Operating margin was -135.5% in Q1 2026, with R&D spending of $33.86M and G&A of $26.20M far exceeding revenue. Net loss of -$52.88M in Q1 2026 highlights the cash burn.
- Clinical-stage binary risk: ANAB is a clinical-stage biotech with no approved products. Pipeline failure in Phase 2 trials for rosnilimab or ANB032 could lead to a -80% or more decline, as seen in the 52-week low of $11.40.
- High valuation on EV/Sales: EV-to-Sales of 7.16x is nearly double the PS ratio of 3.83x, reflecting a premium due to net cash. This suggests the market is pricing in significant future revenue that may not materialize.
ANAB Technical Analysis
The stock is in a strong uptrend, with a 1-year price change of +169.3%, significantly outperforming the S&P 500's +18.7% over the same period. Currently trading at $56.80, it sits at 78.5% of its 52-week range (low of $11.40, high of $72.36), indicating the stock is near its highs but not overextended. This positioning suggests strong momentum, though the proximity to the high could imply potential resistance. The 52-week low of $11.40 was set in early 2025, and the stock has since rallied dramatically, reflecting a major re-rating driven by clinical progress.
Beta
0.41
0.41x market volatility
Max Drawdown
-28.4%
Largest decline past year
52-Week Range
$11-$72
Price range past year
Annual Return
+169.3%
Cumulative gain past year
| Period | ANAB Return | S&P 500 |
|---|---|---|
| 1m | +3.3% | -0.4% |
| 3m | +12.8% | +4.5% |
| 6m | +2.5% | +13.9% |
| 1y | +169.3% | +19.0% |
| ytd | +26.4% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ANAB Fundamental Analysis
Revenue has been volatile, with the most recent quarter (Q1 2026) showing revenue of $25.56 million, a YoY decline of -8.0% from $27.77 million in Q1 2025. However, the prior quarter (Q4 2025) saw a massive spike to $108.25 million, driven by a one-time licensing deal, while Q3 2025 had $76.32 million. Excluding these one-time events, the underlying revenue trend is modest, with collaboration revenue fluctuating. The company is not yet profitable on a consistent basis, with a net loss of -$52.88 million in Q1 2026, though it posted profits in Q3 and Q4 2025 due to the licensing revenue. Gross margin is high at 97.6% in Q1 2026, reflecting the nature of collaboration revenue, but operating margins are deeply negative at -135.5% in Q1 2026 due to heavy R&D spending of $33.86 million. The company's balance sheet is strong, with $248.47 million in cash at the end of Q1 2026, a current ratio of 9.07, and a debt-to-equity ratio of 0.38. Free cash flow was negative -$25.94 million in Q1 2026, but the company has sufficient cash to fund operations for the near term.
Quarterly Revenue
$25556000.0B
2026-03
Revenue YoY Growth
-8.0%
YoY Comparison
Gross Margin
97.6%
Latest Quarter
Free Cash Flow
$4409000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ANAB Overvalued?
Given the negative trailing net income, the price-to-sales (PS) ratio is the primary valuation metric, currently at 3.83x, which is below the industry average for biotech companies. The forward PE is 10.85x, implying the market expects significant earnings growth, likely from future licensing deals or product approvals. The EV-to-Sales ratio is 7.16x, indicating a premium to the PS ratio due to the company's net cash position. Compared to the sector, AnaptysBio trades at a discount on a PS basis, but the forward PE suggests high growth expectations. Historically, the PS ratio has ranged from extreme highs (over 600x in 2021) to current levels, indicating the stock is now more reasonably valued relative to its revenue base. The PEG ratio of 0.77 suggests the stock is undervalued relative to its expected earnings growth, but this is based on analyst estimates that may be optimistic.
PE
-70.3x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant. AnaptysBio is not yet profitable on a consistent basis, with a net loss of -$52.88M in Q1 2026 and negative free cash flow of -$25.94M. Revenue is highly volatile, swinging from $25.56M in Q1 2026 to $108.25M in Q4 2025 due to one-time licensing deals, making financial forecasting difficult. The company's operating margin of -135.5% in Q1 2026 underscores the heavy R&D spending required to advance its pipeline. While cash of $248.47M provides a runway, the burn rate implies a need for future financing or additional partnership deals, which could dilute shareholders. The debt-to-equity ratio of 0.38 is manageable, but the company's reliance on external funding for clinical trials remains a key financial risk.
FAQ
The key risks are: 1) Clinical trial failure, which could lead to a -80% decline, as seen in the 52-week low of $11.40. 2) Revenue volatility from one-time licensing deals, making financial performance unpredictable. 3) High cash burn, with negative free cash flow of -$25.94M in Q1 2026, necessitating future financing. 4) Competitive pressure from larger biotech companies targeting similar indications. The most severe risk is the binary outcome of Phase 2 trials, which could either double the stock or cut it by 80%.
The 12-month forecast is bullish, with a base case target of $70-$90 (50% probability), a bull case of $90-$140 (30% probability), and a bear case of $40-$70 (20% probability). The most likely scenario is the base case, where the stock trades around the analyst average of $89.63, assuming steady clinical progress. The bull case would require positive Phase 2 data and a partnership, while the bear case would result from a trial failure. Overall, the expected value is positive, but investors should be prepared for volatility.
AnaptysBio appears fairly valued relative to its growth potential. The PS ratio of 3.83x is below the biotech industry average, and the PEG ratio of 0.77 suggests undervaluation based on expected earnings growth. The forward PE of 10.85x is modest, but it relies on optimistic analyst estimates. The EV-to-Sales ratio of 7.16x is higher, reflecting a premium for its net cash position. Overall, the market is pricing in significant future revenue from its pipeline, but not at an extreme level compared to peers.
AnaptysBio is a good buy for investors with a high risk tolerance and a long-term horizon, given the strong analyst consensus and potential upside. The average target of $89.63 implies +57.8% upside, and even the low target of $70.00 offers +23.2%. However, the stock is highly volatile and subject to binary clinical trial outcomes. A failure in Phase 2 trials could lead to a -80% decline, so it is not suitable for conservative investors. For those who can withstand potential drawdowns, the risk/reward is attractive.
AnaptysBio is more suitable for long-term investment, given the clinical development timeline. Phase 2 trials are ongoing, and potential FDA approval is years away. The stock is highly volatile, with a beta of 0.403, but its 52-week range shows swings of over 500%. Short-term trading is risky due to binary events like data readouts. A minimum holding period of 3-5 years is recommended to allow pipeline catalysts to materialize. For investors with a long-term horizon, the potential rewards justify the risks.